Kathryn Kolibaba, MD

Kathryn Kolibaba, MD, associate chair of hematology research program, US Oncology, discusses an ongoing phase 2 study of brentuximab vedotin (Adcetris) with as frontline therapy in patients with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).

Videos

Kathryn Kolibaba, MD, associate chair of hematology research program, US Oncology, discusses an ongoing phase 2 study of brentuximab vedotin (Adcetris) with as frontline therapy in patients with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL).<br />
&nbsp;

A Study Examining Brentuximab Vedotin in Patients With High-Risk Large B-Cell Lymphoma

Kathryn Kolibaba, MD, hematologist, Compass Oncology, US Oncology Network, discusses results from the phase II trial dubbed Pyramid Trial (NCT00931918). The open-label trial examined a combination of R-CHOP and bortezomib in patients with untreated non-germinal center B-cell-like (non-GCB) subtype diffuse large cell lymphoma (DLBCL).

Kolibaba says it came as a surprise to researchers that the addition of bortezomib to R-CHOP did not produce a significant outcome. She said despite this, researchers still gathered important information about diagnostic criteria from across the United States that will allow for a quicker accrual for upcoming trials.

Kathryn Kolibaba, MD, discusses results from the phase II trial dubbed Pyramid Trial. The open-label trial examined a combination of R-CHOP and bortezomib in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma.

Kathryn Kolibaba, MD | Authors

Articles

A Study Examining Brentuximab Vedotin in Patients With High-Risk Large B-Cell Lymphoma

Dr. Kathryn Kolibaba on R-CHOP and Bortezomib Combo in Diffuse Large B-Cell Lymphoma